RE:TSTConsidering 50% of phase 3 completed drugs eventually get FDA approval, and the FDA told us to submit with current data set after seeing phase 12&3 data as well as the 39 patient 3b safety add on, we have a pretty good shot at an FDA approval. Nowhere near as low as your 7.6% claim is??? Nothing is written in stone, but this is pretty darn close. There is virtually no other treatment for refractory patients aside from removal of the bladder. The symposium notes on bladder cancer have one of the FDA panel members suggesting Uroocidin ( MCNA) is needed option for BC patient with no other options. I'd say we have a whole lot better than 50/50 chance. Sujan from seeking alpha suggests 80% likely hood of FDA greenlight.
Beech